Geron (GERN -11.2%), up 22% earlier, is now in the red on more than triple normal volume in apparent reaction to the lack of a decision from Johnson & Johnson on continuing with imetelstat. Investors appeared to be jumping the gun ahead of J&J’s pharma update this morning considering previous guidance that its decision on imetelstat will be made by month-end.
In Johnson & Johnson’s pharma business update this morning, imetelstat was cited under “potential filings” for 2019 – 2021 (slide #15).
Previously: Geron down 13% in early trading on extended timeline for imetelstat study, risk that Janssen will bail (Aug. 1, 2017)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.